EP0912178A4 - Verfahren zur behandlung des bluthochdrucks - Google Patents

Verfahren zur behandlung des bluthochdrucks

Info

Publication number
EP0912178A4
EP0912178A4 EP97926817A EP97926817A EP0912178A4 EP 0912178 A4 EP0912178 A4 EP 0912178A4 EP 97926817 A EP97926817 A EP 97926817A EP 97926817 A EP97926817 A EP 97926817A EP 0912178 A4 EP0912178 A4 EP 0912178A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating hypertension
hypertension
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97926817A
Other languages
English (en)
French (fr)
Other versions
EP0912178A1 (de
Inventor
Donald R Gehlert
Mitchell I Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0912178A1 publication Critical patent/EP0912178A1/de
Publication of EP0912178A4 publication Critical patent/EP0912178A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97926817A 1996-05-24 1997-05-23 Verfahren zur behandlung des bluthochdrucks Withdrawn EP0912178A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1826696P 1996-05-24 1996-05-24
US18266P 1996-05-24
PCT/US1997/009225 WO1997044035A1 (en) 1996-05-24 1997-05-23 Methods of treating hypertension

Publications (2)

Publication Number Publication Date
EP0912178A1 EP0912178A1 (de) 1999-05-06
EP0912178A4 true EP0912178A4 (de) 2000-08-16

Family

ID=21787068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97926817A Withdrawn EP0912178A4 (de) 1996-05-24 1997-05-23 Verfahren zur behandlung des bluthochdrucks

Country Status (5)

Country Link
EP (1) EP0912178A4 (de)
JP (1) JP2000511193A (de)
AU (1) AU3149297A (de)
CA (1) CA2255910A1 (de)
WO (1) WO1997044035A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927125D0 (en) * 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001402A1 (en) * 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
EP0591040A1 (de) * 1992-09-30 1994-04-06 Sanofi Quarternäre basische Amide als Tackykinine Antagoniste
WO1994007843A1 (en) * 1992-09-25 1994-04-14 Merck Sharp & Dohme Limited Cyclohexyl amine derivatives and their use as tachykinin antagonists
EP0699665A1 (de) * 1994-06-10 1996-03-06 Eli Lilly And Company Imidazolin-Derivate, deren Herstellung und deren Verwendung als Tachykinin-Rezeptor Antagonisten
WO1996026183A1 (en) * 1995-02-22 1996-08-29 Novartis Ag 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
EP0739892A2 (de) * 1995-04-24 1996-10-30 Ciba-Geigy Ag Chromon-Derivate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001402A1 (en) * 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
WO1994007843A1 (en) * 1992-09-25 1994-04-14 Merck Sharp & Dohme Limited Cyclohexyl amine derivatives and their use as tachykinin antagonists
EP0591040A1 (de) * 1992-09-30 1994-04-06 Sanofi Quarternäre basische Amide als Tackykinine Antagoniste
EP0699665A1 (de) * 1994-06-10 1996-03-06 Eli Lilly And Company Imidazolin-Derivate, deren Herstellung und deren Verwendung als Tachykinin-Rezeptor Antagonisten
WO1996026183A1 (en) * 1995-02-22 1996-08-29 Novartis Ag 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
EP0739892A2 (de) * 1995-04-24 1996-10-30 Ciba-Geigy Ag Chromon-Derivate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002140086 *
See also references of WO9744035A1 *

Also Published As

Publication number Publication date
CA2255910A1 (en) 1997-11-27
JP2000511193A (ja) 2000-08-29
AU3149297A (en) 1997-12-09
WO1997044035A1 (en) 1997-11-27
EP0912178A1 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
GB9617780D0 (en) Method of treatment
IL125829A0 (en) Method of sharing cryptokey
PL333364A1 (en) Novel compounds and method of using them
ZA965088B (en) Methods of preventing or treating allergles
PL338082A1 (en) Methods of treating obesity
ZA971709B (en) Method of increasing testosterone
GB9715295D0 (en) Novel method of treatment
AU2807297A (en) Methods of treating wastewater
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
GB9715298D0 (en) Novel method of treatment
SG64990A1 (en) Method of treating polyolefin
GB9715306D0 (en) Novel method of treatment
AU2051397A (en) Method of treating alopecia
PL341667A1 (en) Method of treating cooped
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
EP0912178A4 (de) Verfahren zur behandlung des bluthochdrucks
PL329476A1 (en) Method of treating sleeplessness
EP1143998A4 (de) Behandlung von hypertonie
IL114096A0 (en) Methods of treating hypertension and improving impaired renal function
ZA984421B (en) Method of treating isolated systolic hypertension
GB9602404D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000704

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20001002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021203